Cat. No.: HY-17423

Abacavir

6 Cited Publications

Customer Review

Based on 6 publication(s) in Google Scholar

Abacavir is an orally active and competitive nucleoside reverse transcriptase inhibitor. Abacavir can inhibits the replication of HIV. Abacavir shows anticancer activity in prostate cancer cell lines. Abacavir can trespass the blood-brain-barrier and suppresses telomerase activity.

For research use only. We do not sell to patients.

Purity: 99.88%
CAS No.: 136470-78-5
Formula: C₁₄H₁₈N₆O
Molecular Weight:286.34

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Abacavir Chemical Structure

CAS No.: 136470-78-5

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (6)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
C3H/3T3	CC₅₀	>20 μM Compound: 1	Cytostatic concentration required to inhibit C3H/3T3 cell proliferation Cytostatic concentration required to inhibit C3H/3T3 cell proliferation	[PMID: 15887959]
C3H/3T3	EC₅₀	8.8 μM Compound: 1	Effective concentration against murine moloney sarcoma virus in C3H/3T3 cells Effective concentration against murine moloney sarcoma virus in C3H/3T3 cells	[PMID: 15887959]
CCRF-CEM	CC₅₀	78 μM Compound: 1	Cytostatic concentration required to inhibit CEM cell proliferation Cytostatic concentration required to inhibit CEM cell proliferation	[PMID: 15887959]
CCRF-CEM	EC₅₀	1.9 μM Compound: 1	Effective concentration against human immunodeficiency virus type 1 in CEM cells Effective concentration against human immunodeficiency virus type 1 in CEM cells	[PMID: 15887959]
CCRF-CEM	EC₅₀	3 μM Compound: 1	Effective concentration against human immunodeficiency virus type 2 (ROD) in CEM cells Effective concentration against human immunodeficiency virus type 2 (ROD) in CEM cells	[PMID: 15887959]
CCRF-CEM	EC₅₀	3 μM Compound: 1	Effective concentration against human immunodeficiency virus type 2 in CEM cells Effective concentration against human immunodeficiency virus type 2 in CEM cells	[PMID: 15887959]
CCRF-CEM	CC₅₀	83 μM Compound: Abacavir	Cytotoxicity against CEM cell line Cytotoxicity against CEM cell line	[PMID: 16458506]
CCRF-CEM	EC₅₀	1.6 μM Compound: Abacavir	Antiviral activity against HIV1 replication in CEM cell line Antiviral activity against HIV1 replication in CEM cell line	[PMID: 16458506]
CCRF-CEM	CC₅₀	>250 μM Compound: 11, ABC	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 24177359]
CCRF-CEM	EC₅₀	18 μM Compound: 11, ABC	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24177359]
CCRF-CEM	EC₅₀	23 μM Compound: 11, ABC	Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24177359]
CCRF-CEM	IC₅₀	>250 μM Compound: 11, ABC	Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against human CEM cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
HEL	CC₅₀	200 μM Compound: 1	Cytostatic concentration required to inhibit HEL cell proliferation Cytostatic concentration required to inhibit HEL cell proliferation	[PMID: 15887959]
HeLa	IC₅₀	170 μM Compound: 11, ABC	Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis Cytostatic activity against human HeLa cells assessed as growth inhibition after 3 days by particle counting analysis	[PMID: 24177359]
HepG2	CC₅₀	110 μM Compound: 1	Cytostatic concentration required to inhibit Hep G2 cell proliferation Cytostatic concentration required to inhibit Hep G2 cell proliferation	[PMID: 15887959]
HepG2 2.2.15	EC₅₀	5.6 μM Compound: 1	Effective concentration against HBV in Hep G2.2.15 cells Effective concentration against HBV in Hep G2.2.15 cells	[PMID: 15887959]
HepG2 2.2.15	EC₅₀	5.6 μM Compound: 1	Effective concentration againstHBV in Hep G2.2.15 cells Effective concentration againstHBV in Hep G2.2.15 cells	[PMID: 15887959]
L1210	IC₅₀	>250 μM Compound: 11, ABC	Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis Cytostatic activity against mouse L1210 cells assessed as growth inhibition after 2 days by particle counting analysis	[PMID: 24177359]
MT2	CC₅₀	190 μM Compound: Abacavir	Cytotoxicity against human MT2 cells Cytotoxicity against human MT2 cells	[PMID: 18029175]
MT2	CC₅₀	190 μM Compound: 5, abacavir	Cytotoxicity against human MT2 cells after 5 days Cytotoxicity against human MT2 cells after 5 days	[PMID: 19179082]
MT2	EC₅₀	0.32 μM Compound: 5, abacavir	Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay	[PMID: 19179082]
MT4	EC₅₀	7.3 μM Compound: 1	Effective concentration against human immunodeficiency virus type 2 in MT-4 cells Effective concentration against human immunodeficiency virus type 2 in MT-4 cells	[PMID: 15887959]
PBL	EC₅₀	0.2 μM Compound: 1	Effective concentration against human immunodeficiency virus type 1 in PBL cells Effective concentration against human immunodeficiency virus type 1 in PBL cells	[PMID: 15887959]

In Vitro

Abacavir (15 and 150 μM, 0-120 h) inhibits cell growth, affects cell cycle progression, induces senescence and modulates LINE-1 mRNA expression in prostate cancer cell lines^[1].
Abacavir (15 and 150 μM, 18 h) significantly reduces cell migration and inhibits cell invasion^[1].
Abacavir induces fat apoptosis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

PC3, LNCaP and WI-38
Concentration:

15 and 150 μM
Incubation Time:

0, 24, 48, 72 and 96 h
Result:

Showed a dose-dependent growth inhibition on PC3 and LNCaP.

Cell Cycle Analysis^[1]

Cell Line:

PC3 and LNCaP
Concentration:

150 μM
Incubation Time:

0, 18, 24, 48, 72, 96 and 120 h
Result:

Caused a very high accumulation of cells in S phase in PC3 and LNCaP cells, and G2/M phase increment was observed in PC3 cells.

Cell Migration Assay ^[1]

Cell Line:

PC3 and LNCaP
Concentration:

15 and 150 μM
Incubation Time:

18 h
Result:

Significantly reduced cell migration.

Cell Invasion Assay^[1]

Cell Line:

PC3 and LNCaP
Concentration:

15 and 150 μM
Incubation Time:

18 h
Result:

Significantly inhibited cell invision.

In Vivo

Abacavir (100 and 200 mg/kg, p.o.; 4 h) dose-dependently promoted thrombus formation^[2].
Abacavir (50 mg/kg/d; i.p.; 14 d) with 0.1 mg/kg/d Decitabine (HY-A0004) enhances survival of high-risk medulloblastoma-bearing mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male mice (9-weeks old, 22-30 g) - wild-type (WT) C57BL/6 or homozygous knockout (P2rx7 KO, B6.129P2-P2rx7^tm1Gab/J)^[2]
Dosage:

2.5, 5 and 7.5 μg/mL, 100 μL or 100 and 200 mg/kg
Administration:

Intrascrotal or oral administration for 4 h
Result:

Dose-dependently promoted thrombus formation.

Animal Model:

NSG^TM mice, patient-derived xenograft (PDX) cells of non-WNT/non-SHH, Group 3 and of SHH/ TP53-mutated medulloblastoma^[3]
Dosage:

50 mg/kg/d with 0.1 mg/kg/d Decitabine
Administration:

Intraperitoneal injection, daily for 14 days
Result:

Inhibited tumor growth and enhanced mouse survival.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 136470-78-5
Appearance Solid
Molecular Weight 286.34
Formula C₁₄H₁₈N₆O
Color White to off-white
SMILES

NC1=NC(NC2CC2)=C3N=CN([C@H]4C=C[C@@H](CO)C4)C3=N1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Neuronal FGF13 Inhibits Mitochondria-Derived Damage Signals to Prevent Neuroinflammation and Neurodegeneration in a Mouse Model of Parkinson's Disease. [Abstract]

2025 May 8:e2503579. PMID: 40344619
Aging Cell

2026 Jan 20;25(2):e70352.
J Mol Liq

2018 Feb;251:345-357.
Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
Antiviral Res

Seasonal coronavirus infections trigger NLRP3 inflammasome activation in macrophages but is therapeutically targetable. [Abstract]

2023 Aug:216:105674. PMID: 37459896
ASN Neuro

Exposure to Frontline Antiretroviral Dolutegravir Disrupts Oligodendrocyte Development Across Differentiation Stages. [Abstract]

2026;18(1):2647877. PMID: 41904696

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (349.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2 mg/mL (6.98 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4924 mL

17.4618 mL

34.9235 mL

5 mM

0.6985 mL

3.4924 mL

6.9847 mL

10 mM

0.3492 mL

1.7462 mL

3.4924 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 3.33 mg/mL (11.63 mM); Clear solution; Need ultrasonic and warming

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Carlini F, et al. The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines. PLoS One. 2010 Dec 3;5(12):e14221. [Content Brief]

[2]. Collado-Diaz V, et al. Abacavir Induces Arterial Thrombosis in a Murine Model. J Infect Dis. 2018 Jun 20;218(2):228-233. [Content Brief]

[3]. Gringmuth M, et al. Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir. Int J Mol Sci. 2022 Mar 30;23(7):3815. [Content Brief]

[4]. McComsey GA, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS. 2005 Jan 3;19(1):15-23. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.4924 mL	17.4618 mL	34.9235 mL	87.3088 mL
H₂O / DMSO	5 mM	0.6985 mL	3.4924 mL	6.9847 mL	17.4618 mL
DMSO	10 mM	0.3492 mL	1.7462 mL	3.4924 mL	8.7309 mL
	15 mM	0.2328 mL	1.1641 mL	2.3282 mL	5.8206 mL
	20 mM	0.1746 mL	0.8731 mL	1.7462 mL	4.3654 mL
	25 mM	0.1397 mL	0.6985 mL	1.3969 mL	3.4924 mL
	30 mM	0.1164 mL	0.5821 mL	1.1641 mL	2.9103 mL
	40 mM	0.0873 mL	0.4365 mL	0.8731 mL	2.1827 mL
	50 mM	0.0698 mL	0.3492 mL	0.6985 mL	1.7462 mL
	60 mM	0.0582 mL	0.2910 mL	0.5821 mL	1.4551 mL
	80 mM	0.0437 mL	0.2183 mL	0.4365 mL	1.0914 mL
	100 mM	0.0349 mL	0.1746 mL	0.3492 mL	0.8731 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Abacavir

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Chinese Baijiu Compound Library

Classic FDA-Approved Drug Library

3D Diverse Fragment Library

Publications Citing Use of MedChemExpress (MCE) Abacavir

All HIV Isoforms

Biological Activity

Chemical Information

Publications (6)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Abacavir Related Classifications

Cat. No.: HY-17423